Inoue Hiroyasu, Yasuda Yukiharu, Hattori Kinya, Shimizu Takashi, Matsumoto Masae, Yabe Miharu, Yabe Hiromasa, Tsuchida Fumiko, Tanaka Yumiko, Hosoi Gaku, Sako Masahiro, Kato Shunichi
Department of Pediatrics, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Int J Hematol. 2003 May;77(4):399-407. doi: 10.1007/BF02982652.
The present study compares immune reconstitution after allogeneic cord blood transplantation (CBT) and CD34+ stem cell transplantation (CD34-SCT) with that after bone marrow transplantation (BMT). Eighty-eight children who underwent CBT (20 patients), BMT (58), and CD34-SCT (10) were enrolled, and lymphocytes and T-, B-, and natural killer-lymphocyte subsets were monitored for more than 5 years after transplantation. CBT recipients showed significant ircreases in (1) total lymphocyte counts (P < .001), (2) CD4+/CD8+ cell ratios (P < .01), (3) CD4+ and CD4+CD45RA+ cells (P < .001), (4) CD8+CD11b+ cells (P < .001), and (5) CD19+ and CD19+CD5+ cells (P < .0001) and marked decreases in the frequencies of CD8+ and CD8+CD11b- cells (P < .0001). CD34-SCT recipients showed lower lymphocyte counts in the first 6 months and an emergence of lymphocyte and CD4+CD45RA+ cells at approximately 9 months and 1 year. Both CBT and CD34-SCT recipients showed increased frequencies of CD56+ cells at 1 month (CD34-SCT versus BMT, P < .001) but decreased frequencies after 6 months (CBT versus BMT, P < .001). Lymphoproliferative responses to exogenous interleukin 2 were constantly lower in CBT and CD34-SCT recipients than in BMT recipients. These results suggest that the delay in immune reconstitution after CBT in the early phase was mainly qualitative and related to the immaturity of cells, whereas the delay in CD34-SCT was mainly quantitative in the first several months.
本研究比较了异基因脐血移植(CBT)、CD34+干细胞移植(CD34-SCT)和骨髓移植(BMT)后的免疫重建情况。纳入了88例接受CBT(20例)、BMT(58例)和CD34-SCT(10例)的儿童,并在移植后5年多的时间里监测淋巴细胞以及T、B和自然杀伤淋巴细胞亚群。CBT受者出现了以下显著增加:(1)总淋巴细胞计数(P <.001),(2)CD4+/CD8+细胞比值(P <.01),(3)CD4+和CD4+CD45RA+细胞(P <.001),(4)CD8+CD11b+细胞(P <.001),以及(5)CD19+和CD19+CD5+细胞(P <.0001),同时CD8+和CD8+CD11b-细胞的频率显著降低(P <.0001)。CD34-SCT受者在最初6个月淋巴细胞计数较低,在大约9个月和1年时出现淋巴细胞和CD4+CD45RA+细胞。CBT和CD34-SCT受者在1个月时CD56+细胞频率均增加(CD34-SCT与BMT相比,P <.001),但在6个月后频率降低(CBT与BMT相比,P <.001)。CBT和CD34-SCT受者对外源性白细胞介素2的淋巴细胞增殖反应始终低于BMT受者。这些结果表明,CBT早期免疫重建延迟主要是质量性的,与细胞不成熟有关,而CD34-SCT在最初几个月的延迟主要是数量性的。